Hims & Hers Health (HIMS) Faces FTC And Class Action Lawsuits, Is The Stock Still Undervalued?
Hims & Hers Health (HIMS) is in focus after the Federal Trade Commission filed a lawsuit over its health data sharing, billing, and subscription cancellation practices, followed by class action complaints from multiple plaintiff firms.
For Hims & Hers Health, the legal and regulatory scrutiny appears to be weighing on sentiment, with the share price down 12.45% over the past 30 days and year to date, while the 1-year total shareholder return has declined 42.76%, even though the 3-year total shareholder return remains very large.
Stress test your thesis on Hims & Hers Health by comparing this legal overhang with other companies that currently screen as 82 resilient stocks with low risk scores.
After a sharp pullback tied to the FTC and class action headlines, Hims & Hers Health now sits at a very different entry point than earlier this year. Does it make more sense to step in now, or to wait for more clarity on value?
Most Popular Narrative: 83.8% Undervalued
On the most followed narrative, Hims & Hers Health has a fair value of $171.19 versus the recent share price of $27.71. This frames a very large gap that the narrative treats as a long term opportunity rather than a short term reaction to headlines.
The thesis is not about one medication, one category or one quarter.
It is about a company repeatedly following the same playbook while expanding its addressable market.
More customers. More categories. More countries. More services per customer. Higher ARPU. Better operating leverage.
That is the Multi-Dimensional Growth Engine.
The combination of execution, expanding opportunity and improving economics suggests that the disconnect between Hims'' underlying growth potential and current market pricing remains substantial, both in the short and long term.
According to Deep_Insights, this fair value hinges on a specific mix of revenue expansion, margin improvement and a future earnings multiple that is usually reserved for large scale growth companies. This framework is presented as still pointing to a higher valuation even as Hims & Hers Health deals with regulatory pressure and current losses.
Result: Fair Value of $171.19 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Hims & Hers Health still faces clear risks, including an unresolved FTC lawsuit over data and billing practices and ongoing losses despite revenue of US$2,578.112m.
Find out about the key risks to this Hims & Hers Health narrative.
Next Steps
If the mixed sentiment around Hims & Hers Health has you undecided, it may be useful to move beyond waiting for unanimous opinion. Take a closer look at the company data, then weigh both sides with the 2 key rewards and 2 important warning signs.
Looking for more ideas beyond Hims & Hers Health?
If Hims & Hers Health has sharpened your focus, do not stop there. Broaden your watchlist now so you are not relying on a single story.
- Target dependable income and stability by reviewing companies in the 11 dividend fortresses.
- Pursue strong fundamentals with less financial strain through the list of solid balance sheet and fundamentals (52 results).
- Spot future leaders early by scanning the 19 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com